The press release is largely strategic narrative with limited concrete financials. The $1M in AME revenue is a positive signal but small relative to the $19M market cap. Monitor for actual revenue ramp in upcoming financial reports and progress on medical business monetization. The name change and quantum partnerships could attract speculative interest, but the lack of hard guidance keeps the stock in high-risk territory.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · May 11 $0.4070entry
- T+1 · 6mo ago +2.70%α +2.84% · $0.4180
- T+5 · 6mo ago −8.60%α −8.51% · $0.3720
- T+20 · 5mo ago +293.12%α +293.42% · $1.60
- T+60 · due 3mo ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Inspira Technologies issued a shareholder letter outlining a strategic pivot into quantum connectivity and AME, reporting over $1M in recent AME transactions and a joint development agreement with Qarakal Quantum. The company is also pursuing monetization of its medical business. The letter is heavy on forward-looking statements and lacks hard financial data beyond the $1M revenue figure, making the near-term impact uncertain.
Key Financial Metrics
Key Facts
- Generated over $1 million from recent AME transactions, majority already received in cash.
- Signed a joint development agreement with Qarakal Quantum Ltd. for quantum connectivity solutions.
- Shareholders approved name change to QTREX Quantum Ltd.
- Deployed a commercial AME system at a Tier-1 U.S. defense customer.
- Commenced implementation process with one of the 'Magnificent Seven' U.S. technology companies.
- Actively working to sell parts of the medical business, targeting a term sheet by Q3 2026.
- Terminated ATM and SEPA facilities in March 2026.
- Medical business burn rate has been reduced.
- INSPIRA ART100 has been used in over 40 patients clinically.
Financial Impact
Over $1 million in recent AME transactions; no revenue or EPS figures provided for the overall company.
Risk Factors
- No reported revenue or EPS figures for the overall company; all financial claims are forward-looking.
- Quantum connectivity strategy is pre-revenue and highly speculative.
- Medical business monetization may not materialize as planned.
- High cash burn and reliance on non-dilutive capital from medical sale.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3291784 |
Track record
13 reports on IINN
3 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +308.27% at T+5 after the May 18, 2026 report. 3 of 3 went positive at some point.
Filters
- Oct 9, 20265w ago 6-K Neutral 4/10 No price data
- May 29, 202624w ago Press Release Mixed 5/10 Entry $3.07 to $1.87 ▼ −39.09% −38.80% vs SPY
- May 18, 202626w ago Press Release Bullish 5/10 Entry $0.3723 to $1.52 ▲ +308.27% +306.65% vs SPY
- May 11, 202627w ago Press Release Neutral 5/10 Viewing Entry $0.4070 to $0.3720 ▼ −8.60% −8.51% vs SPY
- May 1, 202628w ago Press Release Neutral 4/10 Entry $0.4680 to $0.4500 ▼ −3.85% −6.19% vs SPY
- Apr 16, 202630w ago Press Release Bullish 6/10 Entry $0.4950 to $0.5400 ▲ +9.09% +8.11% vs SPY
- Apr 14, 202630w ago Press Release Neutral 3/10 Entry $0.4750 to $0.5800 ▲ +22.11% +20.71% vs SPY
- Apr 13, 202631w ago Press Release Mixed 5/10 Entry $0.5080 to $0.5870 ▲ +15.55% +12.26% vs SPY
- Apr 6, 202632w ago Press Release Neutral 4/10 Entry $0.4110 to $0.5080 ▲ +23.60% +19.47% vs SPY
- Apr 6, 202632w ago Press Release Bullish 7/10 Entry $0.4110 to $0.5080 ▲ +23.60% +19.47% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers